ConductScience.org, home
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
API referenceFor AI assistants

Trial · NCT00306202

Adverse events759

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 759

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherNeutropeniaBlood and lymphatic system disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose117
otherNeutropeniaBlood and lymphatic system disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose117
otherNeutropeniaBlood and lymphatic system disordersStratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose024
otherPancytopeniaBlood and lymphatic system disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose117
otherPancytopeniaBlood and lymphatic system disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose017
otherPancytopeniaBlood and lymphatic system disordersStratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose024
otherSplenomegalyBlood and lymphatic system disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose017
otherSplenomegalyBlood and lymphatic system disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose017
otherSplenomegalyBlood and lymphatic system disordersStratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose224
otherThrombocytopeniaBlood and lymphatic system disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose117
otherThrombocytopeniaBlood and lymphatic system disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose317
otherThrombocytopeniaBlood and lymphatic system disordersStratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose324
otherPalpitationsCardiac disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose317
otherPalpitationsCardiac disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose117
otherPalpitationsCardiac disordersStratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose024
otherEar discomfortEar and labyrinth disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose217
otherEar discomfortEar and labyrinth disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose017
otherEar discomfortEar and labyrinth disordersStratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose024
otherEar painEar and labyrinth disordersStratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose217
otherEar painEar and labyrinth disordersStratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose317

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00306202/events

API referenceFor AI assistants